Donald Allen Williams bought $29k of PALI
director at PALISADE BIO, INC.. 20,000 shares at an average of $1.44, traded Oct 1, 2026, filed Oct 5, 2026.
Score components
- +15RoleDirector
- +5Trade size$29k at market
- 0Relative to holdingsHoldings up 1.3%
- 0Price contextNo price history yet
- 0ClusterNo other insider buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001493152-26-045772, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Oct 1, 2026 | POpen-market purchase Common Stock | +10,000 | $1.42 | $14k | 1,580,294 | 7 d ago |
| Oct 2, 2026 | POpen-market purchase Common Stock | +10,000 | $1.46 | $15k | 1,590,294 | 7 d ago |
Related signals
Other insiders at PALISADE BIO, INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 15Weak | PALIsell PALISADE BIO, INC. | John David Finley CEO, CFO | $6,818 3,896 shares | -12% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.